Martin and Harris Laboratories Limited Unlisted Share Price
Martin and Harris Laboratories Limited unlisted share price is ₹875 per share (indicative, as of 17 Oct 2026). Minimum ticket ₹25,000 (lot of 28 shares), the same for every company. Sector: Consumer. Status: unlisted, no DRHP on record.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 17 Oct 2026, 22:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; Martin and Harris Laboratories Limited’s indicative price is ₹875 per share as of 17 Oct 2026, a lot of 28 shares.
Key facts
- Indicative price
- ₹875 per share
- Price as of
- 17 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 28 shares
- Sector
- Consumer
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 17 Oct 2026, 22:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 17 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE03VV01015: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- Unlisted. No DRHP on record.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative move: -2.2% over 3 months · -7.9% over 1 year.
Key figures
| Market cap | ₹349.65 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 28 |
| P/E ratio | 5.27x |
| ROE | 7.33% |
| Book value | ₹1,749.15 |
| Face value | ₹10 |
| 52-week high | ₹950 |
| 52-week low | ₹850 |
| ISIN | INE03VV01015 |
| Dividend yield | 0.3% |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 205 | 146 | 107 |
| PAT | 68.0 | 40.4 | 66.3 |
| EPS (₹) | 170 | 101 | 166 |
About the company
Martin and Harris Laboratories Limited is an India-based pharmaceutical company incorporated in 1993 and headquartered in Gurgaon, Haryana. It is associated with the Apeejay Stya & Svran group and operates in the manufacturing of pharmaceuticals, medicinal chemicals and botanical products, with manufacturing units in Himachal Pradesh and Uttarakhand.
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Gurugram, Haryana.
Registry
- ISIN: INE03VV01015
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 17 Oct 2026
Company facts
| CIN | U24239HR1993PLC033630 |
|---|---|
| Incorporated | 1993 |
| ISIN | INE03VV01015 |
| Face value | ₹10 |
| Registered office | NH-8, Delhi Jaipur Highway, Village Pachgaon (Fazalwas), Distt. Gurgaon, Haryana 000000, India |
| Shares outstanding | 39,96,040 |
| Lot size | 28 shares |
| Minimum units | 15 |
| DRHP | Not filed |
Financial statements (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY25 vs FY24 |
|---|---|---|---|---|---|
| Revenue | 186 | 205 | 146.15 | 107.43 | −26.5% |
| EBITDA | 70 | 72 | 26 | 8.4 | −67.7% |
| Profit before tax | 93 | 92 | 55 | 83 | +50.9% |
| Profit after tax | 70 | 68 | 40.43 | 66.3 | +64% |
| EPS (₹) | 175.44 | 170.43 | 101.17 | 165.93 | +64% |
| Net margin | — | — | 13.8% | 36.6% | +22.8 pts |
| Share capital | — | — | 4 | 4 | +0% |
| Reserves & surplus | — | — | 629.07 | 694.97 | +10.5% |
| Net worth | — | — | 633.07 | 698.97 | +10.4% |
| Fixed assets | — | — | 17.76 | 52.22 | +194% |
| Investments | — | — | 34.17 | 3.68 | −89.2% |
| Trade receivables | — | — | 1.91 | 34.47 | ×18.0 |
| Trade payables | — | — | 15.83 | 20.71 | +30.8% |
| Cash from operations | — | — | 19.01 | 273.56 | ×14.4 |
| Cash from investing | — | — | 20.66 | −271.97 | profit to loss |
| Cash from financing | — | — | 1.07 | 3.11 | +190.7% |
| Net cash generated | — | — | −0.58 | 2.7 | loss to profit |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹875 | dealer reference, 17 Oct 2026 |
| Market cap | ₹349.65 Cr | price × 39,96,040 shares |
| P/E | 5.27x | price ÷ EPS ₹165.93 (FY25) |
| P/B | 0.5x | price ÷ book value ₹1,749.15 |
| EPS | ₹165.93 | per share, FY25 |
| Book value | ₹1,749.15 | per share, latest books |
| RoE | 7.33% | return on equity, latest FY |
| Debt / equity | 0.03 | latest balance sheet |
| Dividend yield | 0.3% | at the indicative price |
| Face value | ₹10 | per share |
| 52-week range | ₹850 – ₹950 | 317 dated quotes, last 12 months |
| Shares outstanding | 39,96,040 | per company record |
Shareholding pattern
| Category | Holder | % of equity |
|---|---|---|
| Promoters | Chang Investchem Pvt Ltd (Promoter) | 37.53% |
| Others | Aessen Pvt Ltd | 20.51% |
| Others | Acme Network S.A. | 20.07% |
| Public | Others / Public | 21.88% |
Promoters 37.53% · Public 21.88% · Others 40.58%
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Sushma Paul Berlia | Co-Promoter / Chairperson (Apeejay Group) | — |
| Ajay Grover | Director | — |
| Gopal Krishnan Nigam | Director | — |
| Shankar Lakshman Laad | Director | — |
| Harman Singh Thakur | Director | — |
Business model
Martin and Harris Laboratories Ltd is a pharmaceutical company established in 1993. The company describes itself as engaged in research and manufacturing of finished dosage forms. It offers diversified products and drug-development and manufacturing solutions with value-added services. Its manufacturing units serve domestic and international markets and have experience making complex dosage forms and specialty formulations. The Roorkee facility, which began production in 2008, has manufacturing equipment operating with quality-control techniques under international guidelines.
It makes tablets, capsules, dry syrup, liquid orals, ointments and drug powder and has a separate hormonal-products section; it also has newer finished-dosage-form technologies, including dispersible and modified-release tablets. The Gagret unit began production in 2010 and supports business continuity and capacity expansion. The company also says it collaborates with finished-dosage-form, API and contract-manufacturing organizations to commercialize technology in certain specialized products.
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Undated | Other | Ashok Chandra (DIN 09764909) had a change in designation; the MGT-7 records the nature as Change in designation. (29 Sep 2023) | — | Desk note |
Reports and filings
No filings uploaded yet.
Annual reports
Frequently asked questions
What does Martin and Harris Laboratories Limited do?
Martin and Harris Laboratories Limited is an India-based pharmaceutical company incorporated in 1993 and based in Gurgaon, Haryana. It manufactures pharmaceuticals, medicinal chemicals and botanical products and is associated with the Apeejay Stya & Svran group, with manufacturing units in Himachal Pradesh and Uttarakhand. It also runs an investment and treasury portfolio that contributes a meaningful part of its income.
Is Martin and Harris Laboratories Limited listed on the stock exchange?
No. Martin and Harris Laboratories Limited is currently an unlisted company, meaning its shares are not traded on the NSE or BSE. Its equity is exchanged privately in the unlisted market. The company has the ISIN INE03VV01015 and CIN U24239HR1993PLC033630.
How can I buy Martin and Harris Laboratories Limited unlisted shares?
Unlisted shares are bought and sold through private off-market transactions and settled into your demat account. To learn about availability, indicative pricing and the transfer process, you can contact the desk, who can walk you through the steps.
What are the risks of investing in Martin and Harris Laboratories Limited unlisted shares?
Unlisted and pre-IPO shares carry higher risk and lower liquidity than listed securities. There is no guarantee a company will list on an exchange, exiting a position can be difficult, prices can vary widely between buyers and sellers, and disclosures are typically less frequent than for listed firms. Consider your own risk tolerance and consult a qualified adviser before any decision.
What is the Martin and Harris Laboratories Limited unlisted share price today?
The indicative over-the-counter reference price is ₹875 per share as of 17 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is Martin and Harris Laboratories Limited listed on a stock exchange?
Not yet. Martin and Harris Laboratories Limited changes hands in the unlisted market, over the counter and settle into your demat account through NSDL and CDSL.
What is the minimum investment in Martin and Harris Laboratories Limited?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of Martin and Harris Laboratories Limited?
INE03VV01015. Holdings are settled in demat form through NSDL and CDSL.
How do I buy Martin and Harris Laboratories Limited unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if Martin and Harris Laboratories Limited lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- Martin and Harris Laboratories Limited annual report 2023-24 · FY 2023-24 · martinharrislabs.com
- BuyUnlistedShares indicative price series for Martin and Harris Laboratories Limited, dated daily · since 12 Sep 2025 (343 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Martin and Harris Laboratories Limited unlisted share price”, https://buyunlistedshares.com/unlisted-shares/martin-and-harris-laboratories-limited, as of 17 Oct 2026.
Other Consumer unlisted shares
- A V Thomas & Co. Limited · ₹12,500
- Anglo French Drugs and Industries · ₹1,075
- Anheuser Busch Inbev India (AB InBev) · ₹555
- Apollo Fashion International · ₹44
- Arch Pharmalabs Limited · ₹85
- Auckland Jute Co. Limited · ₹189
Enquire to buy Martin and Harris Laboratories Limited · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 17 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
